Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7017773 in Adolescents and Adults With Autism Spectrum Disorder
NCT04299464Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of alogabat in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Roche. Primary endpoint: Adaptive Behavior Composite Score of the Vineland Adaptive Behavior Scales, Third Edition at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
alogabat
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04299464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299464.